F-star Therapeutics (FSTX) Gets a Buy Rating from H.C. Wainwright

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on F-star Therapeutics (FSTXResearch Report), with a price target of $35.00. The company’s shares closed last Monday at $7.22.

According to TipRanks.com, Trucchio is a 2-star analyst with an average return of 0.8% and a 48.1% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Arrowhead Pharmaceuticals, and Milestone Pharmaceuticals.

F-star Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.33.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spring Bank Pharmaceuticals, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA.